Skip to main content

Table 2 Changes of laboratory findings

From: Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function

Initial laboratory finding

Pre-SGLT2i

Post-SGLT2i

Difference

P-value

White blood cell count (103/μL)

7.45 ± 1.50

7.35 ± 1.44

0.12 ± 1.23

0.354

Hemoglobin (g/dL)

14.4 ± 1.36

15.0 ± 1.41

–0.58 ± 0.72

 < 0.001

Platelet count (103/μL)

232.3 ± 57.5

232.2 ± 62.9

0.75 ± 23.5

0.767

Protein (g/dL)

7.22 ± 0.46

7.41 ± 0.49

–0.20 ± 0.38

0.004

Albumin (g/dL)

4.55 ± 0.35

4.51 ± 0.32

0.03 ± 0.27

0.486

Blood urea nitrogen (mg/dL)

14.7 ± 4.58

16.7 ± 4.65

–2.02 ± 3.58

 < 0.001

Creatinine (mg/dL)

0.85 ± 0.19

0.86 ± 0.20

–0.01 ± 0.10

0.603

Glomerular filtration rate (mL/min/1.73m2)

92.9 ± 13.9

91.5 ± 17.0

1.10 ± 10.4

0.324

Total cholesterol (mg/dL)

146.0 ± 36.7

144.2 ± 37.1

1.64 ± 23.0

0.503

Trigliceride (mg/dL)

183.5 ± 173.8

169.6 ± 210.6

7.91 ± 105.7

0.482

High-density lipoprotein (mg/dL)

46.2 ± 9.90

47.4 ± 10.9

–0.94 ± 6.51

0.174

Low-density lipoprotein (mg/dL)

84.1 ± 32.7

80.1 ± 26.1

4.20 ± 21.1

0.063

Fasting glucose (mg/dL)

163.9 ± 35.9

134.3 ± 29.4

28.8 ± 38.6

 < 0.001

Hemoglobin A1C (%)

8.08 ± 1.09

7.31 ± 1.12

0.76 ± 0.73

 < 0.001

Glycoalbumin (%)

20.2 ± 4.55

18.5 ± 4.47

2.48 ± 2.89

 < 0.001

NT-proBNP (pg/mL)

44.5 ± 39.8

42.2 ± 40.9

1.82 ± 32.8

0.745

Body mass index (kg/m2)

28.2 ± 4.0

27.3 ± 4.0

–0.9 ± 0.9

 < 0.001

  1. Values are presented as mean ± standard deviation
  2. SGLT2i sodium-glucose cotransporter type 2 inhibitor, NT-proBNP N-terminal pro-brain natriuretic peptide